Fundraising Fox

Avelas Biosciences

2 known investors

Clinical-stage drug-device company developing pegloprastide (AVB-620) for real-time surgical margin detection in cancer surgery.

Investors · 2

Torrey Pines InvestmentSan Diego
AlexandriareportedPasadena

In the news

Avelas Biosciences raises $20 mln | PE Hubpehub.com · Aug 2016Avelas Biosciences Completes $20 Million Series C Financingprnewswire.com · Aug 2016Avelas Biosciences raises $7.4M for cancer visualization tech; FDA clears new test for acute renal failure; | Fierce Biotechfiercebiotech.com · Sep 2014Avelas Biosciences Extends Series B Financing to $7.4 Million to Support Clinical Development of Real-Time Cancer Visualization Technologyprnewswire.com · Sep 2014Avelas Biosciences Raises $6.85M To Test Its Real-Time Breast Cancermddionline.com · Jan 2014Avelas Biosciences Closes $6.85 Million in Series B Financing to Advance Real-Time Cancer Visualization Technology to Clinical Proof-of-Conceptprnewswire.com · Jan 2014

Frequently asked questions

What does Avelas Biosciences do?
Clinical-stage drug-device company developing pegloprastide (AVB-620) for real-time surgical margin detection in cancer surgery.
Who are Avelas Biosciences's investors?
Avelas Biosciences's investors include Torrey Pines Investment, Alexandria.